Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Chemotherapy. University Hospital, Linkoping, Sweden

Survival: 8.6 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Gemzar
Country: Sweden
City/State/Province: Linkoping
Hospital: University Hospital
Journal: Link
Date: 11/2005

Patients: This Phase III study involved a total of 325 patients. Patients were divided into two groups: Group A had 169 patients and Group B had 156 patients. The median age for patients in Group A was 66 and most patients had stage IV cancer. For Group B, the median age was also 66 and most patients also had stage IV cancer.

Treatment: The treatment for patients in Group B consisted of one chemotherapeutic drug -- gemcitabine.

Toxicity: Grade 4 toxicities included: leukopenia and thrombocytopenia.

Results: The median survival for Group B was 8.6 months.

Support: The study was supported by a grant from Eli Lilly and Co. Gemcitabine (Gemzar) is manufacture by Eli Lilly.

Correspondence: Christer Sederholm

E-mail to a Friend Email Physician More Information